All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Merck Resolves Claims Related to Vioxx for $950 Million

December 1, 2011
By Amy Ritter, PhD
Article

The justice department announced that Merck has agreed to pay $950 million to resolve criminal charges and civil claims related to its promotion and marketing of the painkiller Vioxx.

The justice department announced that the US pharmaceutical company Merck & Co. has agreed to pay $950 million to resolve criminal charges and civil claims related to its promotion and marketing of the painkiller Vioxx.

The criminal charges relate to off-label marketing of Vioxx. Under the agreement, Merck will plead guilty to a misdemeanor for its illegal promotional activity and will pay a $321,636,000 criminal fine. Vioxx was approved for three indications in 1999, but not approved for use in rheumatoid arthritis patients until 2002. However, Merck marketed the painkiller for use in rheumatoid arthritis patients between 1999 and 2002 and received a Warning Letter from FDA in November 2001, for the practice.

Merck has also agreed to a civil settlement under which it will pay $628,364,000 to resolve additional allegations regarding off-label marketing of Vioxx and false statements about the drug’s cardiovascular safety. The settlement resolves allegations that Merck representatives made inaccurate, unsupported, or misleading statements about Vioxx’s cardiovascular safety in order to increase sales of the drug, resulting in payments by the federal government. According to a press release from Merck, as a result of the settlement, the US and the participating states have released Merck from civil liability related to the government’s allegations regarding the sale and marketing of Vioxx in the US, They also state that the civil settlement does not constitute any admission by Merck of any liability or wrongdoing. However, previously disclosed litigation with seven states remains outstanding.

Finally, as part of the settlement, Merck has also agreed to enter into an expansive corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services (HHS-OIG), which will strengthen the system of reviews and oversight procedures imposed on the company. Although Vioxx was voluntarily withdrawn from the market in 2004, this ongoing monitoring of Merck’s conduct is aimed to deter and detect similar conduct in the future.

Bruce N. Kuhlik, executive vice-president and general counsel of Merck, said in the company press release, “Merck recognizes the importance of robust compliance programs and is committed to adhering to the law and to our fundamental values and standards. We believe that the settlement of this lengthy investigation is in the best interests of our stakeholders, and we look forward to focusing on our mission to save and improve lives around the world.”


See related Pharm Tech articles:

GlaxoSmithKline Agrees in Principle to $3-Billion Settlement with the US Government

Pfizer Takes $2.3-Billion Hit

AstraZeneca Fined $520 Million for Off-Label Marketing

Recent Videos
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content

The mRNA or messenger Ribonucleic Acid white text for medical or outbreak concept 3d rendering | Image Credit: ©niphon - adobe.stock.com

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

Cheryl Barton
June 24th 2025
Article

mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Pharmacist weighing chemical | Image Credit: © Kzenon - stock.adobe.com

Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs

Paul L. Pluta;Nishant B. Thakar;Varanya Chaiyaperm
June 23rd 2025
Article

Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling.


Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.


Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

EIT Health Ireland–UK Expands European Network with Three New Members

Patrick Lavery
June 19th 2025
Article

NIBRT, Firefinch, and eg technology will join the center, adding to its collective of healthcare innovators.


Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

BASF Opens GMP Manufacturing Facility in Michigan

Susan Haigney
June 19th 2025
Article

The new facility offers cleanroom packaging and high-sensitivity analytical testing.

Related Content

The mRNA or messenger Ribonucleic Acid white text for medical or outbreak concept 3d rendering | Image Credit: ©niphon - adobe.stock.com

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

Cheryl Barton
June 24th 2025
Article

mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Pharmacist weighing chemical | Image Credit: © Kzenon - stock.adobe.com

Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs

Paul L. Pluta;Nishant B. Thakar;Varanya Chaiyaperm
June 23rd 2025
Article

Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling.


Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.


Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

EIT Health Ireland–UK Expands European Network with Three New Members

Patrick Lavery
June 19th 2025
Article

NIBRT, Firefinch, and eg technology will join the center, adding to its collective of healthcare innovators.


Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

BASF Opens GMP Manufacturing Facility in Michigan

Susan Haigney
June 19th 2025
Article

The new facility offers cleanroom packaging and high-sensitivity analytical testing.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.